Sanya Sukduang, a Partner in the Bio/Pharmaceutical Practice Group at Finnegan and Partner-In-Charge of Diversity and Inclusion, practices patent litigation in the pharmaceutical (Hatch-Waxman), biologics, biotechnology, medical devices, diagnostics, and chemical sciences in federal district court and before the Court of Appeals for the Federal Circuit. Mr. Sukduang has also advised clients on an array of issues, including due diligence investigations, strategic patent portfolio planning, and reexaminations before the U.S. Patent and Trademark Office. He has conducted all aspects of pre-trial, trial, post-trial, and inter partes review (IPR) proceedings before the PTAB. Mr. Sukduang has extensive experience in cases arising from the filing of Abbreviated New Drug Applications (ANDA). He advises clients on an array of issues concerning biologics, including due diligence investigations and strategic patent portfolio planning. Mr. Sukduang has an active pro bono practice assisting families in adopt and custody matters in the District of Columbia.
In addition to his litigation practice, Mr. Sukduang lectures frequently on the topic of biosimilars, is a member of the Dean's Diversity Council at the Washington College of Law, and has sat on the Board of Directors for the Asian Pacific American Bar Association for the District of Columbia.
He received his BS in Biology from Boston College and his JD, cum laude, from the American University Washington College of Law.